TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 150 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,727,074 | -35.4% | 4,667,458 | +10.9% | 0.00% | -50.0% |
| Q2 2023 | $64,623,852 | -27.9% | 4,207,282 | +5.6% | 0.00% | 0.0% |
| Q1 2023 | $89,613,520 | +21.2% | 3,984,594 | +13.3% | 0.00% | 0.0% |
| Q4 2022 | $73,929,829 | -11.3% | 3,515,446 | +4.0% | 0.00% | 0.0% |
| Q3 2022 | $83,323,000 | +3.2% | 3,381,610 | +1.5% | 0.00% | 0.0% |
| Q2 2022 | $80,707,000 | -18.6% | 3,330,819 | -13.4% | 0.00% | 0.0% |
| Q1 2022 | $99,152,000 | -17.7% | 3,847,535 | -0.9% | 0.00% | -33.3% |
| Q4 2021 | $120,462,000 | +28.5% | 3,880,873 | +0.4% | 0.00% | +50.0% |
| Q3 2021 | $93,738,000 | +67.5% | 3,865,481 | +0.8% | 0.00% | +100.0% |
| Q2 2021 | $55,949,000 | -44.0% | 3,834,756 | -4.2% | 0.00% | -66.7% |
| Q1 2021 | $99,920,000 | +7.7% | 4,001,588 | +17.5% | 0.00% | 0.0% |
| Q4 2020 | $92,788,000 | – | 3,404,443 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |